Prognosis of patients with colonic carcinoma before, during and after implementation of complete mesocolic excision
Top Cited Papers
- 25 May 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 103 (9), 1220-1229
- https://doi.org/10.1002/bjs.10183
Abstract
Background The implementation of complete mesocolic excision (CME) for colonic cancer was accompanied by other important changes, including more patients with early diagnosis by screening and the introduction of adjuvant chemotherapy in patients with stage III disease. The contribution of CME remains unclear. Methods In this observational study, data from patients with stage I–III colonic carcinoma were analysed by comparing five time intervals: 1978–1984 (pre-CME), 1985–1994 (CME development), 1995–2002 (CME implementation), 2003–2009 (CME) and 2010–2014 (CME), with a special focus on indicators of process and outcome quality. Results During the observed periods, the median age of patients increased (from 65 to 67 years), there were more right-sided carcinomas (from 17·0 to 32·4 per cent), more stage I disease (from 14·0 to 27·7 per cent) and fewer patients with regional lymph node metastases (from 42·7 to 32·0 per cent). The proportion of patients with pN0 disease and at least 12 examined regional lymph nodes increased (from 84·8 to 100 per cent) as did the R0 resection rate (from 97·0 to 100 per cent). Overall morbidity increased, whereas the in-hospital mortality rate was stable (range 1·8–3·7 per cent). Use of adjuvant chemotherapy in stage III colonic carcinoma increased from 0 to 79 per cent. The improvement in outcome quality was more evident in stage III than in stage I–II tumours. In stage III, the 5-year locoregional recurrence rate decreased from 14·8 to 4·1 per cent (P = 0·046) and the 5-year cancer-related survival rate increased from 61·7 to 80·9 per cent (P = 0·010). Conclusion With CME, the quality indicators of process and outcome quality improved, especially in stage III colonic carcinoma. Adjuvant chemotherapy in stage III and multidisciplinary approaches in patients with metachronous distant metastases contributed to further outcome improvement.This publication has 24 references indexed in Scilit:
- Short-term outcomes after complete mesocolic excision compared with ‘conventional’ colonic cancer surgeryBritish Journal of Surgery, 2016
- Improved survival after an educational project on colon cancer management in the county of Stockholm – A population based cohort studyEuropean Journal of Surgical Oncology, 2015
- Extent of surgery in cancer of the colon: Is more better?World Journal of Gastroenterology, 2015
- Complete mesocolic resection and extended lymphadenectomy for colon cancer: a systematic reviewColorectal Disease, 2014
- The lymph node ratio optimises staging in patients with node positive colon cancer with implications for adjuvant chemotherapyInternational Journal of Colorectal Disease, 2014
- Extended Lymphadenectomy in Colon Cancer is CrucialWorld Journal of Surgery, 2013
- Prognostic Value of the Lymph Node Ratio in Stage III Colorectal Cancer: A Systematic ReviewAnnals of Surgical Oncology, 2010
- Definition and grading of anastomotic leakage following anterior resection of the rectum: A proposal by the International Study Group of Rectal CancerSurgery, 2010
- Complete mesocolic excision (CME): A “novel” concept?Journal of Surgical Oncology, 2009
- Standardized surgery for colonic cancer: complete mesocolic excision and central ligation – technical notes and outcomeColorectal Disease, 2009